Marshall Wace
ARTV

Marshall Wace’s Artiva Biotherapeutics ARTV Stock Holding History

Marshall Wace’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-79,559
Closed -$341K – 3761
2025
Q4 		$341K Buy
+79,559
New +$300K ﹤0.01% 2401
2025
Q3 		– Sell
-52,213
Closed -$78.8K – 3512
2025
Q2 		$78.8K Buy
+52,213
New +$110K ﹤0.01% 2565

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Marshall Wace's ARTV Position: Q1 2026 in Review

Marshall Wace sold out of Artiva Biotherapeutics (ARTV) in Q1 2026, closing a stake of 79,559 shares — an estimated $341K sold.

Marshall Wace first reported a position in ARTV in Q2 2025 and held it in 2 quarters. The position peaked at $341K in Q4 2025. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • Marshall Wace reported no remaining Artiva Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 79,559 Artiva Biotherapeutics shares in Q1 2026, an estimated $341K.
  • Marshall Wace first reported a position in Artiva Biotherapeutics in Q2 2025 and held it in 2 quarters.
  • Marshall Wace's Artiva Biotherapeutics position peaked at $341K in Q4 2025.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.